Inovio Pharmaceuticals (NASDAQ: INO) stock did not continue to fall after it lost 25% of its price on April 23. That shows the thing is not too bad, right? Investors want to know more information about its vaccine development in order to make better decisions.
And now, the timetable has came out, the first quarter 2021 financial results will be released by the company after the market close on May 10, and a live conference call and webcast will be held by the company that day to discuss financial results and provide a general business update regarding its DNA medicines platform, including the company's ongoing vaccine developments for COVID-19.
According to reports, the company and its China partner, Advaccine, will plan to launch multiple clinical centers worldwide for the phase 3 clinical study of its INO-4800 vaccine. Base on the current global pandemic situation, these clinical centers may cover Latin America, Europe, Southeast Asia and other regions. Of course, China may become the largest market for its vaccines.
Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.